Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Oct 7.

Published in final edited form as: J Neuroimaging. 2019 Jun 7;29(5):624–629. doi: 10.1111/jon.12642

Figure 1. — The flex point model for ¹H MRS metabolite ratios.

In the x axis, 0 indicates the actual age of symptom onset for converters with MAPT mutation. The metabolite ratios are in the y axis. The black line shows the predicted values calculated from the flex-point models. NAA/Cr ratios did not have a “flex-point” during the follow-up time window (A). The increase of the presumed glial marker mI/Cr accelerated in 1.86 years prior to symptom onset, and continued to increase in time (B). A similar trajectory of decrease was observed the neuronal marker NAA/mI ratio 2.09 years prior to symptom onset (C). NAA = N-acetylaspartate; Cr = creatine; mI = myo-inositol.

Figure 1. — The flex point model for ¹H MRS metabolite ratios.

In the x axis, 0 indicates the actual age of symptom onset for converters with MAPT mutation. The metabolite ratios are in the y axis. The black line shows the predicted values calculated from the flex-point models. NAA/Cr ratios did not have a “flex-point” during the follow-up time window (A). The increase of the presumed glial marker mI/Cr accelerated in 1.86 years prior to symptom onset, and continued to increase in time (B). A similar trajectory of decrease was observed the neuronal marker NAA/mI ratio 2.09 years prior to symptom onset (C). NAA = N-acetylaspartate; Cr = creatine; mI = myo-inositol.